SEC Comment Letter 0000000000-25-009537 to PDS Biotechnology Corp (PDSB)
PDS Biotechnology Corp
Date: Sept. 4, 2025 · CIK: 0001472091 · Accession: 0000000000-25-009537
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-289942
Letter
September 4, 2025 Frank Bedu-Addo, Ph.D. President and Chief Executive Officer PDS Biotechnology Corporation 303A College Road East Princeton, NJ 08540 Re:PDS Biotechnology Corporation Registration Statement on Form S-3 Filed August 29, 2025 File No. 333-289942 Dear Frank Bedu-Addo Ph.D.: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at 202-551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Patrick O’Malley, Esq.
Show Raw Text
September 4, 2025
Frank Bedu-Addo, Ph.D.
President and Chief Executive Officer
PDS Biotechnology Corporation
303A College Road East
Princeton, NJ 08540
Re:PDS Biotechnology Corporation
Registration Statement on Form S-3
Filed August 29, 2025
File No. 333-289942
Dear Frank Bedu-Addo Ph.D.:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Chris Edwards at 202-551-6761 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Patrick O’Malley, Esq.